

Q2 --Figure 2: (SEQ ID NO: 1 and SEQ ID NO: 3) Insulin secretory signal - pST peptide
sequence.--

Please insert at the end of the specification, the attached paper copy of a Sequence Listing.

REMARKS

In response to the Notification, Applicants submit a Sequence Listing both in paper and computer readable form in full compliance with the Sequence Rules as set forth in 37 C.F.R. § 1.821 through 1.825.

In accordance with 37 C.F.R. § 1.821(f) the undersigned representative hereby states that the content of the Sequence Listing of the attached paper copy of the Sequence Listing of the above-captioned application and the computer readable copy filed herewith on a computer-readable disk are believed to be the same. Moreover, the paper copy and above-referenced computer readable copy do not introduce new matter into the application.

Prompt and favorable consideration on the merits of the application is respectfully requested.

Applicants respectfully request any extension of time deemed necessary. If necessary, please also charge any deficient fees, or credit any overpayment of fees, to Deposit Account No. 500417. A duplicate copy of this communication is enclosed.

[SIGNATURE PAGE TO FOLLOW]

Respectfully submitted,

MCDERMOTT, WILL & EMERY

By: Kelli N. Watson
Kelli N. Watson
Registration No. 47,170

September 17, 2001

McDermott, Will & Emery
600 Thirteenth Street, N.W.
Washington, D.C. 20005-3096
Telephone: (202) 756-8351
Facsimile: 202) 756-8087

Attachment: Paper Copy of a Sequence Listing
Computer Readable Form of a Sequence Listing



ATTACHMENT

Version With Markings To Show Changes Made

IN THE SPECIFICATION:

Figure 1: (SEQ ID NO:2 and SEQ ID NO: 4) Insulin secretory signal - pST gene construct.

Figure 2: (SEQ ID NO: 1 and SEQ ID NO: 3) Insulin secretory signal - pST peptide sequence.

050179-0088